GLYT1 encephalopathy
medical condition

GLYT1 encephalopathy is a rare autosmal recessive, metabolic and genetic disorder which is caused by a mutation in the SLC6A9 gene.
The main features of this disorder are: severely diminished muscle tone, respiratory failure, absence of neonatal reflexes, encephalopathy, reduced consciousness and unresponsiveness, also it can present with arthrogryposis/ligament laxity, and normal serum glycine.
About 10 cases had been reported as of 2022.
Symptoms
Someone with GLYT1 encephalopathy can present with facial dysmorphism, arthrogryposis and diminished muscle tone that progresses into muscle hypertonicity with so called startle-like clonus (which means that they have startle-like response to vocal and visual stimuli) and normal serum glycine level.
Facial features of this disorder might include: thin eyebrows, saddle nose, retrognathism, long myopathic face, piggy noses, tent-shaped mouth, low-set ears.
Diagnosis
Diagnosis of this disorder can be suspected by symptoms (such as: drowsiness, diminished muscle tone, and seizures) and by high glycine levels in cerebrospinal fluid and normal levels of enzymes and glycine in plasma, consequently diagnosis can be confirmed by genetic testing of GLYT1.
Cause
This disorder is caused by a mutation in a gene SLC6A9, which encodes Sodium- and chloride-dependent glycine transporter 1 protein, which is located on chromosome 1.
Pathophysiology
Glycine is the simplest amino acid, that doesn't have any stereoisomers. Glycine participates in protein synthesis, but it can act as neurotransmitter, in the spinal cord and in the brain stem, it acts as inhibitory neurotransmitter by activating glycine channels. Although it has excitatory effect in neocortex (by co-activating NMDAR).
“GLYT1 encephalopathy” enters the record as medical condition. Crown Archives preserves that source wording while asking what GLYT1, encephalopathy and medical can confirm, complicate or overturn.
Why this record matters
“GLYT1 encephalopathy” is worth following because a concise public description often conceals a longer documentary argument. Here, GLYT1, encephalopathy and medical provides the most credible route into that argument.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Mar 10, 2026. The linked authority identifier is Q135512461. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2022.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “GLYT1 encephalopathy”, its source revision and the description used here.
- Expand the search: follow GLYT1 encephalopathy primary sources, GLYT1 encephalopathy archive and GLYT1 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “GLYT1 encephalopathy”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “GLYT1 encephalopathy” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.